Miniatura

Fitxers

867665.pdf (1.2 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2024-09-27

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/215666

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41375-024-02416-2

Resum

Hydroxyurea (HU) constitutes the first-line treatment in most patients with essential thrombocythemia (ET), but criteria for changing therapy are not clearly established. The prognostic value of complete hematological response (CHR) and resistance/intolerance to HU was assessed in 1080 patients from the Spanish Registry of ET, classified according to revised IPSET-Thrombosis stratification (Very low- n = 61, Low- n = 83, Intermediate- n = 261, and High-risk n = 675). With a median therapy duration of 5 years, CHR was registered in 720 (67%) patients (1-year probability 51%) and resistance/intolerance in 219 (20%) patients (5-years probability 13%). After correction by other risk factors, High-risk patients achieving CHR showed a reduced risk of arterial thrombosis (HR: 0.35, 95%CI: 0.2-0.6, p = 0.001) and a trend towards lower risk of venous thrombosis (HR: 0.45, 95%CI: 0.2-1.02, p = 0.06) whereas no association was observed for intermediate- or low-risk patients. In comparison with non-responders, intermediate- and high-risk patients achieving CHR had longer survival and lower myelofibrosis incidence. Development of resistance/intolerance to HU, mainly cytopenia, was associated with higher probability of myelofibrosis but no effect on survival or thrombotic risk was demonstrated. In conclusion, CHR with HU is associated with better outcomes and might be an early indicator for selecting candidates to second-line clinical trials.

Matèries

Quimioteràpia, Medul·la òssia, Trastorns de les plaquetes sanguínies, Medicaments

Matèries (anglès)

Chemotherapy, Bone marrow, Blood platelet disorders, Drugs

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

SANTALIESTRA, Marta, GARROTE I ORDEIG, Marta, NOYA, María soledad, PÉREZ ENCINAS, Manuel, SENÍN, Alicia, PÉREZ LÓPEZ, Raúl, FERRER MARÍN, Francisca, CARREÑO TARRAGONA, Gonzalo, CABALLERO, Gonzalo, MAGRO, Elena, VÉLEZ, Patricia, CORTÉS VÁZQUEZ, Miguel ángel, MORETÓ, Ana, ANGONA, Anna, PASTOR GALÁN, Irene, GUERRA, José maría, GARCÍA HERNÁNDEZ, Carmen, MATA, María isabel, STUCKEY, Ruth, GÓMEZ CASARES, María teresa, FOX, Laura, CUEVAS, Beatriz, GARCÍA GUTIÉRREZ, Valentín, TRIGUERO, Ana, ARELLANO RODRIGO, Eduardo, HERNÁNDEZ BOLUDA, Juan carlos, ÁLVAREZ LARRÁN, Alberto. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia. _Leukemia_. 2024. [consulta: 27 de gener de 2026]. ISSN: 0887-6924. [Disponible a: https://hdl.handle.net/2445/215666]

Exportar metadades

JSON - METS

Compartir registre